Measuring drug levels for inflammatory bowel disease treatments
Treatments studied
Part of Digestive system clinical trials.
This study looks at different ways to measure the amount of biologic drugs in your blood. It is for people with inflammatory bowel disease who are about to start a new biologic therapy or have never taken one before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- You have not taken any biologic medicines before, or your doctor decides you need to start one like infliximab, adalimumab, vedolizumab, or ustekinumab.
- You are not currently taking antibiotics and have not used probiotics or antibiotics in the past month.
- You do not have other active autoimmune diseases, active tumors, or severe mouth problems.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with inflammatory bowel disease (Crohn's or ulcerative colitis) do not respond to certain biologic treatments. Researchers will use advanced testing (multi-omics) to better understand treatment response. If you are starting or have just started treatment with infliximab, adalimumab, vedolizumab, or ustekinumab, you may be able to join.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study looks at whether certain blood markers can help measure disease activity in people with Crohn's disease or ulcerative colitis. It involves reviewing medical records and may include a colonoscopy if you have one done as part of your routine care.
This trial tests whether a personalized dosing method (using your own drug levels) can help people with Crohn's or ulcerative colitis maintain better control with vedolizumab or ustekinumab. It aims to see if adjusting doses based on your individual needs leads to fewer flare-ups and better outcomes.
This study compares intravenous (IV) and under-the-skin (subcutaneous) biologic drugs for people with Crohn's disease or ulcerative colitis. It helps doctors understand if switching from the IV form to a shot is as effective and well-tolerated.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.